2.4.0.8130 - Disclosure - Arcion License Agreement - Additional Information (Detail)truefalsefalse1false USDfalsefalse$eol_PE71016---1310-Q0006_STD_92_20130630_0http://www.sec.gov/CIK0001103021duration2013-03-31T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$eol_PE71016---1310-Q0006_STD_91_20120630_0http://www.sec.gov/CIK0001103021duration2012-04-01T00:00:002012-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$eol_PE71016---1310-Q0006_STD_181_20130630_0http://www.sec.gov/CIK0001103021duration2013-01-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$eol_PE71016---1310-Q0006_STD_182_20120630_0http://www.sec.gov/CIK0001103021duration2012-01-01T00:00:002012-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Research and Development Arrangement, Contract to Perform for Others [Line Items]2false 4bdsi_CommonStockLockingPeriodbdsi_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse009 monthsfalsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaCommon stock locking period.No definition available.false0Common stock locking period3false 4bdsi_MilestonePaymentsIncreasedbdsi_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse80000008000000USD$falsetruefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryMilestone payments increased.No definition available.false2Milestone payments increased4false 4us-gaap_ResearchAndDevelopmentExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1275821512758215USD$falsefalsefalse2truefalsefalse65465796546579USD$falsefalsefalse3truefalsefalse2479038324790383USD$falsefalsefalse4truefalsefalse1125818911258189USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 false2Research and development expense5false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5false USDtruefalse$eol_PE71016---1310-Q0006_STD_181_20130630_0_923497x921516http://www.sec.gov/CIK0001103021duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseUS [Member]us-gaap_StatementGeographicalAxisxbrldihttp://xbrl.org/2006/xbrldicountry_USus-gaap_StatementGeographicalAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0US [Member]6true 3us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Research and Development Arrangement, Contract to Perform for Others [Line Items]7false 4bdsi_PotentialPaymentsUponAchievementOfPredeterminedSalesbdsi_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse6000000060000000USD$falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryPotential payments upon achievement of predetermined sales.No definition available.false2Potential Payments upon achieving certain pre-determined sales thresholds in the U.S8false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse6false USDtruefalse$eol_PE71016---1310-Q0006_STD_181_20130630_0_923497x921516_926437x932953http://www.sec.gov/CIK0001103021duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseUS [Member]us-gaap_StatementGeographicalAxisxbrldihttp://xbrl.org/2006/xbrldicountry_USus-gaap_StatementGeographicalAxisexplicitMemberfalsefalseMinimum [Member]us-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MinimumMemberus-gaap_RangeAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0US [Member] | Minimum [Member]9true 3us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Research and Development Arrangement, Contract to Perform for Others [Line Items]10false 4bdsi_MilestoneSalesbdsi_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse200000000200000000USD$falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryMilestone sales.No definition available.false2Milestone Sales11false 4bdsi_MilestonePaymentReceivableFromSublicenseesbdsi_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse7000000070000000USD$falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryMilestone payment receivable from sublicensees.No definition available.false2Milestone payment receivable from sublicensees12false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse7false USDtruefalse$eol_PE71016---1310-Q0006_STD_181_20130630_0_926233x957043http://www.sec.gov/CIK0001103021duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseArcion License Agreement [Member]us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxisxbrldihttp://xbrl.org/2006/xbrldibdsi_ArcionLicenseAgreementMemberus-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Arcion License Agreement [Member]13true 3us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Research and Development Arrangement, Contract to Perform for Others [Line Items]14false 4us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssetsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse500516500516falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.No definition available.false1Share issued to Arcion15false 4bdsi_CommonStockSharesIssuedFairValuebdsi_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse21000002100000USD$falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCommon stock shares issued fair value.No definition available.false2Fair market value of unregistered shares issued16false 4bdsi_PotentialPaymentsUponFilingAndAcceptancebdsi_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse25000002500000USD$falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryPotential cash or stock payment upon NDA filing and acceptance.No definition available.false2Potential payments upon filing and acceptance17false 4bdsi_RoyaltyTermDescriptionbdsi_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00The royalty term for any given country is the later of (i) the first date there are no valid claims against any Arcion patent, (ii) expiration of patent exclusivity or (iii) tenth anniversary of the first commercial sale.falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringRoyalty term descriptionNo definition available.false0Royalty term description18false 4us-gaap_ResearchAndDevelopmentExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse21000002100000USD$falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 false2Research and development expense19false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse8false USDtruefalse$eol_PE71016---1310-Q0006_STD_181_20130630_0_926233x957043_926437x932953http://www.sec.gov/CIK0001103021duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseArcion License Agreement [Member]us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxisxbrldihttp://xbrl.org/2006/xbrldibdsi_ArcionLicenseAgreementMemberus-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxisexplicitMemberfalsefalseMinimum [Member]us-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MinimumMemberus-gaap_RangeAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Arcion License Agreement [Member] | Minimum [Member]20true 3us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Research and Development Arrangement, Contract to Perform for Others [Line Items]21false 4bdsi_InitialPaymentForLicenseAgreementbdsi_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse1750000017500000USD$falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryInitial payment for license agreement.No definition available.false2Potential milestone payment upon FDA approval22false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse9false USDtruefalse$eol_PE71016---1310-Q0006_STD_181_20130630_0_926233x957043_926437x923140http://www.sec.gov/CIK0001103021duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseArcion License Agreement [Member]us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxisxbrldihttp://xbrl.org/2006/xbrldibdsi_ArcionLicenseAgreementMemberus-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxisexplicitMemberfalsefalseMaximum [Member]us-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MaximumMemberus-gaap_RangeAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Arcion License Agreement [Member] | Maximum [Member]23true 3us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Research and Development Arrangement, Contract to Perform for Others [Line Items]24false 4bdsi_InitialPaymentForLicenseAgreementbdsi_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse3500000035000000USD$falsetruefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryInitial payment for license agreement.No definition available.false2Potential milestone payment upon FDA approvalfalseArcion License Agreement - Additional Information (Detail) (USD $)NoRoundingNoRoundingUnKnownUnKnowntruefalsefalseSheethttp://www.bdsi.com/taxonomy/role/DisclosureArcionLicenseAgreementAdditionalInformation424